Milk fat globule-epidermal growth factor-factor VIII (MFGE8), also called lactadherin or SED1, is a secreted integrin-binding protein that promotes elimination of apoptotic cells by phagocytes leading to tolerogenic immune responses, and vascular endothelial growth factor (VEGF)-induced angiogenesis: two important processes for cancer development. Here, by transcriptomic analysis of 228 biopsies of bladder carcinomas, we observed overexpression of MFGE8 during tumor development, correlated with expression of genes involved in cell adhesion or migration and in immune responses, but not in VEGF-mediated angiogenesis. To test whether MFGE8 expression was instrumental in bladder tumor development, or a simple consequence of this development, we used genetic ablation in a mouse model of carcinogen-induced bladder carcinoma. We showed that Mfge8 was also upregulated in mouse carcinoma, and that in its absence, Mfge8-deficient animals developed less advanced tumors. Angiogenesis was similar in carcinogen-treated Mfge8-expressing or -deficient bladders, thus ruling out a major role of the proangiogenic function of Mfge8 for its protumoral role. By contrast, the tumorpromoting role of Mfge8 was not observed anymore in mice devoid of adaptive immune system, and human tumors overexpressing MFGE8 where invaded with macrophages and regulatory T cells, thus suggesting that MFGE8/ lactadherin favors development of bladder tumors at least partly by an immune system-dependent mechanism. Our observations suggest future use of MFGE8-inhibiting molecules as therapies of bladder carcinomas, and of a limited number of other human cancers, in which our analysis of public databases also revealed overexpression of MFGE8.
Introduction
Milk fat globule-epidermal growth factor-factor VIII (MFGE8) (Stubbs et al., 1990 ) (also called lactadherin (Taylor et al., 1997) , or SED1 (Ensslin and Shur, 2003) ), is a secreted protein originally identified on milk fat globules, that mediates adhesion to integrin-expressing cells (Taylor et al., 1997) . MFGE8/lactadherin binds to phosphatidylserine at the surface of membrane vesicles (Oshima et al., 2002; Veron et al., 2005) and apoptotic cells (Hanayama et al., 2002) through its FactorVIII-like domain (Shi et al., 2004) , and exposes its EGF-like domain for recognition by avb3/b5 integrins (Andersen et al., 2000) . MFGE8 displays three types of functions. First, MFGE8 promotes phagocytosis of apoptotic cells by avb3/b5 integrin-expressing phagocytes (Hanayama et al., 2002) , endothelial and epithelial cells (Nandrot et al., 2007; Fens et al., 2008) . In Mfge8-deficient mice, impaired elimination of apoptotic cells leads to autoimmune symptoms in old animals (Hanayama et al., 2004) , and mammary gland inflammation after repeated pregnancies in females (Atabai et al., 2005; Hanayama and Nagata, 2005) . MFGE8-mediated phagocytosis of apoptotic cells by macrophages in vitro induces their secretion of regulatory T cell (Treg)-inducing cytokines, thus potentially promoting tolerogenic immune responses (Jinushi et al., 2007) . Second, on endothelial cells, MFGE8/lactadherin binding to avb3/b5 integrins promotes vascular endothelial growth factor (VEGF)-induced survival and proliferation, leading to angiogenesis (Silvestre et al., 2005) . Third, MFGE8 promotes cell/cell and cell/extracellular matrix (ECM) adhesion, through an unknown ligand, during sperm-oocyte interaction (Ensslin and Shur, 2003) , and physiologic migration of epithelial cells in intestine (Bu et al., 2007) and mammary gland (Ensslin and Shur, 2007) .
Elimination of apoptotic cells and tolerogenic immune responses, blood vessel formation, cell migration and interaction with ECM take place during tumor progression in vivo. As MFGE8 promotes all these processes, it could favor tumor growth. Presence of this protein in the serum of breast cancer patients, and in some tumor cells in vitro has been observed long ago (Ceriani et al., 1982; Larocca et al., 1991) . More recently, an increased MFGE8 expression in human melanoma biopsies at the vertical growth stage, a reduced resistance to apoptosis of melanoma cell lines upon MFGE8 depletion, and an increased aggressiveness in vivo of a mouse melanoma cell line engineered to overexpress MFGE8 have been described (Jinushi et al., 2008) . In addition, in a mouse genetic model of pancreatic cancer, Mfge8-deficiency led to development of slightly less invasive tumors (Neutzner et al., 2007) . All these data suggest that MFGE8/lactadherin could have a protumoral role in endocrine pancreas cancer, and in melanoma, but whether this applies to other human cancers is not known.
Here, we addressed this question by analyzing published transcriptomic databases, where we identified 11 cancers with upregulated expression of MFGE8. In bladder carcinoma, we combined a large-scale analysis of the transcriptome of human tumors, and the use of a mouse model of in vivo carcinogen-induced tumor development, applied to Mfge8-deficient animals to propose that MFGE8/lactadherin promotes development of bladder carcinomas, and does so through its functions in the immune system, rather than in angiogenesis.
Results

MFGE8
is overexpressed during human bladder tumor initiation and progression MFGE8 overexpression was recently observed by immunohistochemistry in biopsies of vertical growth phase melanoma, and MFGE8 was proposed to favor melanoma progression (Jinushi et al., 2008) . We assessed whether this observation could be relevant to other types of human tumors, using publicly available transcriptome data compiled in the Oncomine website ( Figure 1a , Supplementary Table S1 ). Out of 26 published studies, we identified 9 types of cancers where MFGE8 was significantly (Po0.001) upregulated in tumors, as compared with normal tissues: adenoid cystic carcinomas of salivary gland, thyroid carcinomas, hepatocellular carcinomas, pancreatic ductal adenocarcinomas, ovarian serous adenocarcinomas, glioblastoma, melanoma, T-cell acute leukemia and B-cell lymphomas. In addition, out of 15 studies with recorded invasiveness status, two cancers, prostate and bladder carcinomas, displayed significant (Po0.001) increase of MFGE8 expression during tumor progression. In agreement with the study of Jinushi et al. (Jinushi et al., 2008) , the MFGE8 messenger RNA was also upregulated during progression of primary human melanoma, but with a lower level of confidence (P ¼ 0.008) (Oncomine analysis of reference (Xu et al., 2008) , data not shown).
We further analyzed the role of MFGE8 in bladder tumor development, using expression data generated in our laboratories. We quantified MFGE8 messenger RNA expression level in two independent human bladder tumor sets, containing, respectively, 52 (Stransky et al., 2006) (Figure 1b ) and 176 tumor samples (Figure 1c) , using Affymetrix microarrays, Santa Clara, CA, USA. In both data sets, MFGE8 was significantly overexpressed in non-muscle-invasive tumors (NMIT) (pTa, pT1) as compared with normal samples, and even the lowest stage and grade of bladder tumor development (pTa) displayed significant MFGE8 overexpression. In addition, MFGE8 expression increased during tumor progression, as shown by its higher expression level in muscle-invasive tumors (MIT) (pT2-pT4) as compared with NMIT (Figures 1b and c) . In both data sets, the group of patients expressing MFGE8 over the median expression level displayed a poorer prognosis than the group expressing MFGE8 below the median (Supplementary Figures S1a and d) . This difference, however, was possibly because of a higher proportion of MIT in the MFGE8-overexpressing group, as the association was not significant when survival analysis was performed on either MIT or NMIT alone (Supplementary Figures s1b, c, e, f). There was no correlation between MFGE8 expression and DNA copy number at the MFGE8 locus (data not shown), suggesting a transcriptional deregulation in tumors. Immunohistochemistry confirmed strong expression of MFGE8/ lactadherin in tumors, and showed its accumulation in carcinoma cells, with also weak staining of blood vessels (Figure 1d ). Hence, MFGE8 expression increases as a function of stage in human bladder tumors.
Expression of MFGE8 and immune response genes are correlated in human tumors To identify the physiological pathways that MFGE8 could affect during bladder tumor progression, we then analyzed the modifications of genome expression together with MFGE8 expression during tumor development, using independently our two transcriptome data sets of human tumor samples. We identified genes with expression profiles correlated or anti-correlated with MFGE8, and genes differentially expressed in all the tumors presenting high or normal MFGE8 expression level (using Spearman's correlation coefficient and significance analysis of microarray (SAM), respectively, Supplementary Table S2 ). The vast majority (91%) of genes with a correlation factor (R) of absolute value above our threshold (that is, 0.5) were positively correlated with MFGE8 (Supplementary Table S2 ). We then used Pathway-Express software to identify the physiological pathways significantly enriched in these two lists of genes generated from independent approaches (Draghici et al., 2007) (Supplementary Table  S3 ). Seven shared pathways associated with MFGE8 overexpression were thus identified (Figure 2 ): three pathways related to the immune system ('Cytokinecytokine receptor interaction', 'Leukocyte transendothelial migration' and 'Complement and coagulation cascades'), and four to adhesion and migration of cells within their environment. Notably, the same seven common pathways were also identified among genes correlated with MFGE8 in the group of MIT or in the group of NMIT (Supplementary Table S4 ), thus showing that these correlations are not merely because of the more extensive presence of stroma in muscleinvasive, as compared with superficial tumors. Interestingly, neither Spearman nor SAM analyses identified the VEGF-mediated angiogenic pathway nor any of the genes specifically involved in the proangiogenic effect of MFGE8/lactadherin (that is, VEGFA, VEGF-receptors, avb3/5 integrins (Silvestre et al., 2005) ) (Supplementary Table S2 ), but several other genes involved in angiogenesis came out in this study: for example, FGFR1, PDGFR, IL8, HGF and IGF1. Thus, MFGE8 overexpression in tumors is accompanied by overexpression of genes involved in physiological pathways taking place during tumor development within its microenvironment, such as interaction with the immune system and with the surrounding cells.
Mfge8 expression favors mouse bladder tumor development To determine whether MFGE8 was having an active role in tumor development, we used a genetic ablation Figure S2b ), whereas in non-BBNtreated bladders, it was only present in blood vessels and at low level in urothelium. Mice expressing (Mfge8 et al., 2005) were killed 20 weeks after the onset of BBN treatment, that is, at a time when the whole range of bladder tumor stages can be observed (McCormick et al., 1981) . Both types of mice presented with significantly enlarged bladders after BBN treatment, as compared with non-treated mice (Po0.0001), but the extent of tumor development was lower in Mfge8-deficient mice ( Figure 3c ). Indeed, mean weight of Mfge8-deficient bladders was 45 mg, as compared with 70 mg for Mfge8-expressing bladders (P ¼ 0.018). Consistently with this macroscopic difference, pathological analysis ( Figure 3d , Supplementary Figure S2a ) showed significantly fewer mice presenting with MIT (XpT2) in the Mfge8-deficient group (2/34 versus 10/31) (P ¼ 0.0093) whereas the occurence of NMIT (pTis and pT1) was identical in both groups. In addition, some Mfge8-deficient mice (4/34) but none of the Mfge8-competent animals (0/32) had not developed any tumor: this difference, however, was not statistically significant (P ¼ 0.114). Thus, the mouse model with genetic ablation of Mfge8 shows that bladder tumor 
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Spearman correlation analysis SAM analysis Figure 2 Identification of biological pathways enriched in genes associated with MFGE8 overexpression in human bladder tumors. A Venn diagram format illustrates the set of genes correlated with MFGE8 expression by either Spearman correlation or SAM analyses, or both, in the whole second tumor set (Supplementary Table S2 ). Genes are grouped in physiological pathways as determined by Pathway-Express software (Supplementary Table S3 ). The same seven pathways were identified by separate Spearman correlation analyses of either MIT or NMIT (Supplementary Table S4 ). Genes written in bolds are shared between pathways. Pathways also identified using the first whole set of tumors are underlined.
MFGE8 promotes bladder tumor development G Sugano et al development is more pronounced in the presence of this gene, that is, that Mfge8 has a protumoral role.
Angiogenesis in mouse bladder tumors does not require Mfge8
We next set out to identify the physiological pathways affected by Mfge8 and responsible for its protumoral activity in mice. As Mfge8 promotes angiogenesis (Silvestre et al., 2005) , we first analyzed vascularization in tumors developed in Mfge8 þ /À or Mfge8 (Figure 4d ). Vegfa and Fgf2, as well as most other cytokines, were expressed at low level (close to background) in all bladders, probably because of the low amount of bladder material available to hybridize the array, but we could detect significant amounts of the proangiogenic cytokine Igf1 in BBNtreated bladders, without any significant differences in expression between Mfge8 þ /À and Mfge8 À/À mice, at any stage of tumor progression ( Figure 4d ). As we have shown before that Mfge8/lactadherin promotes only Vegfa-mediated angiogenesis (Silvestre et al., 2005) , our results suggest that the proangiogenic function of Mfge8 is not the major reason for its protumoral activity, and that Mfge8-independent growth factors can mediate angiogenesis during mouse bladder tumor progression.
The protumoral activity of Mfge8 requires adaptive immune responses in mice Following the hints of the human gene expression analysis, we next questioned the involvement of the immune system in the development of bladder tumors in MFGE8 promotes bladder tumor development G Sugano et al mice. Mfge8 þ /À and Mfge8 À/À mice devoid of a functional adaptive immune system were generated by intercrossing with Rag2 À/À mice, deficient in B and T lymphocytes. Bladder tumor formation upon exposure to BBN was then compared in Rag2
À/À mice. As shown in Figure 5a , there was no difference in bladder weights between the two types of mice 20 weeks after the onset of carcinogen treatment (mean weight ¼ 45 mg in both genotypes). Consistently, pathological evaluation (Figure 5b ) showed identical incidence of pT2 stage tumors in Rag2
þ /À and -Mfge8 À/À mice (3/36 and 2/37, respectively). Tumor development in both Mfge8 þ /À -and Mfge8 À/À -Rag À/À mice was similar to development observed in Mfge8 Figures  3c and d and 5c and d) , suggesting that the protumoral role of Mfge8 is lost when the adaptive immune system is nonfunctional. We cannot exclude, however, that because tumor development was delayed or reduced in Rag À/À mice (in which 35% of animals had not developed tumors at week 20, as compared with 0% in Mfge8
, the protumoral role of Mfge8 could become visible in Rag À/À mice later on.
MFGE8-overexpressing human tumors are infiltrated with macrophages and regulatory T lymphocytes
We next tried to identify the type of immune response potentially involved in the protumoral activity of MFGE8. The design of our mouse study, in which whole bladders were paraffin-embedded at the time of killing, did not allow to obtain these informations because of technical limitations: lack of specificity of antibodies to mouse markers on paraffin-embedded sections, and variable amount of tumoral tissue in the samples (from 10 to 70%) which precluded accurate analysis of gene expression level in the tumors by realtime-quantitative-PCR. We thus used only our human bladder tumor collections to answer this question.
In the transcriptomic data, several immune system genes were overexpressed in correlation with MFGE8 (Figure 2, Supplementary Table S5 ). Such genes included the CD45 ( ¼ PTPRC) pan-hematopoietic marker and the b2 integrin (ITGB2) expressed only in hematopoietic cells, thus confirming the occurrence of an immune infiltrate in these tumors. More specifically, several markers of monocytes, macrophages and dendritic cells were overrepresented in these tumors: CD14 (monocytes), HLA-DPA1 and HLA-DQA1 (MHC class II molecules expressed by professional antigen presenting cells), the Mac1 integrin (ITGAM), Fc receptors (FCGR1A, 2A, 2C), and receptors for macrophage-and granulocyte-specific growth factors (CSF1R, CSF2R, CSF3R). The macrophage-specific markers CD14 and CSF1R (macrophage-colony stimulating factor receptor) presented the highest correlation coefficients with MFGE8 (above 0.6) in the whole tumor set. The correlation coefficients were lower but still relatively high and significant (Po0.0001) when analyzing either only the MIT or the NMIT (Figure 6a) . Accordingly, the two genes were overexpressed in MFGE8-overexpressing tumors, whether total, superficial or muscle-invasive carcinomas were considered (Figure 6b) . In all groups of tumors, paired expression analysis showed very high correlation coefficients (between 0.78 and 0.92) between several different macrophage markers, for example, CD14, CSF1R, CD163 and ITGAM (Supplementary Figure S3) , thus suggesting enhanced infiltration of MFGE8-overexpressing tumors by macrophages expressing these typical surface markers.
The requirement for a functional adaptive immune system for Mfge8-dependent bladder tumor progression in mice also prompted us to analyze the presence of lymphoid immune cells in the MFGE8-overexpressing human tumors. In the transcriptomic data, only one lymphocyte-related gene was more strongly expressed in tumors overexpressing MFGE8, according to SAM analysis (Supplementary Tables S2, S5 ): the CD20 mice. No significant differences between the two groups of mice. The incidence of pT2 carcinomas was significantly lower in Rag2 À/À as compared with Rag2
MFGE8 promotes bladder tumor development G Sugano et al (MS4A1) antigen, expressed by B lymphocytes. Like the macrophage markers, MS4A1 was significantly overexpressed in MFGE8-overexpressing tumors, whether total or only superficial carcinoma were considered (Po0.025, Wilcoxon test, data not shown), suggesting the possible presence of B lymphocytes in these tumors. In addition, as MFGE8-mediated phagocytosis of apoptotic tumor cells by macrophages has been shown to promote the differentiation of regulatory T cells (Tregs) (Jinushi et al., 2007 (Jinushi et al., , 2008 , we asked whether Tregs were present in the bladder tumors. FOXP3 is the transcription factor commonly used as a Treg marker, but the low signal of the probe sets for this gene in the Affymetrix expression data precluded their use to identify Tregs. We thus quantified manually the number of FOXP3-positive T lymphocytes in paraffin-embedded sections of human bladder tumors (Figure 6c) , and we observed a significantly higher infiltration by Tregs of the MFGE8-overexpressing tumors, as compared with those expressing MFGE8 at normal level (Figure 6d , P ¼ 0.03). These results thus suggest that MFGE8-overexpressing bladder tumors are invaded with myeloı¨d and lymphoid hematopoietic cells, including regulatory T lymphocytes. 
Discussion
In this work, we have combined analysis of human bladder tumor sets, and mouse models of bladder tumor development, to unravel the role of MFGE8/lactadherin in bladder tumor development and/or progression to muscle invasive stages, and to propose that this effect is due to an immune function of MFGE8, rather than to its proangiogenic role.
In a mouse model of endocrine pancreas cancer, where Vegfa is required for angiogenesis (Inoue et al., 2002) , Mfge8-deficient mice presented reduced volume of tumors, and slightly impaired angiogenesis (Neutzner et al., 2007) . By contrast, both the human bladder tumor analysis and the in vivo mouse model of bladder tumors suggested an angiogenesis-independent role of MFGE8 in tumor development. This could be explained by the presence of other proangiogenic genes than VEGF, which could account for angiogenesis. Hence, the way MFGE8/lactadherin favors tumor development may depend on the type of cancer analyzed.
Furthermore, we propose here that the protumoral role of MFGE8 in development of bladder carcinoma involves the immune system, as several immune system genes are upregulated together with MFGE8 in human tumors, and as mice devoid of adaptive immune system are not sensitive to the tumor-promoting role of Mfge8. A possible scenario for MFGE8's tumor promoting role is through an induction of tolerogenic T lymphocytes (Tregs) by macrophages: many genes expressed in MFGE8-overexpressing tumors (IL1B, IL6, IL8 and CXCL12 chemokines) suggest an inflammatory environment due to tumor-associated macrophages, (as described before by several groups (Pollard, 2004; Balkwill et al., 2005; Sica et al., 2006; de Visser et al., 2006) ), and likely to promote Tregs (IL10R and TGFB). Indeed, we could show an increased recruitment of Tregs in these tumors. Tregs dampen the activity of effector T cells, and thus prevent excessive immune reactions, such as autoimmunity, but they can also prevent efficient immune responses, especially in the context of tumors. Two recent articles have proposed a regulatory T cell-promoting role for Mfge8/lactadherin in mice: in atherosclerosis (Ait-Oufella et al., 2007) , or in granulocyte monocyte-colony stimulating factor-dependent induction of anti-tumor immune responses (Jinushi et al., 2007) . More recently, the latter group has shown that subcutaneous grafts of mouse melanoma cells transfected with Mfge8 were infiltrated with Mfge8-expressing macrophages, regulatory T cells, and poorly efficient cytotoxic T cells when transplanted in mice (Jinushi et al., 2008) , and thus became more aggressive. In the mouse model of bladder carcinoma, our observation that Mfge8 requires a functional adaptive immune system to promote development also suggests a possible Treg-dependent protumoral role of Mfge8. In addition, other mechanisms, involving B cells (which have been shown to promote tumor progression in a skin-tumor mouse model (de Visser et al., 2005) ) or other types of T cells, could also be at work. Deciphering the exact immune responses involved in bladder tumor development in the mouse carcinogen-induced model, and the role played by Mfge8 expression by tumor, and/ or by the immune and nonimmune stromal component, will be the object of another study.
In conclusion, our work shows that an immunesystem-dependent protumoral activity of MFGE8/ lactadherin takes place during development of bladder carcinomas, and that, in human at least, macrophages and regulatory T cells invading the tumor are possible players of this immune response, as observed in human progressing melanoma and mouse xenografted melanoma cell lines. In addition, co-expression with MFGE8 of several families of genes involved in cells' interaction with their environment and migration (for example, 'Cell Adhesion molecules', 'Focal adhesion', 'ECMreceptor interaction', 'Regulation of actin cytoskeleton', Figure 2 ) can also suggest a role of MFGE8 in the migration and/or metastasis process of bladder carcinoma, as suggested in melanoma (Jinushi et al., 2008) .
Interestingly, Bacillus Calmette-Guerin (BCG) therapy, a well recognized treatment for patients with aggressive superficial (pTa, pT1) tumors, prevents muscle recurrence and invasion probably by promoting anti-tumor immune responses (Sharma et al., 2007) . BCG instillation has been proposed to overcome the tolerance established in the tumor, and switch the immune system towards effective antitumor activity (Saint et al., 2001) . Jinushi et al. (Jinushi et al., 2007) have shown that, in the presence of pathogen-derived ligands and/or necrotic cells, phagocytosis of tumor cells by macrophages is performed in the absence of Mfge8 and results in effective anti-tumor immune responses, whereas in the absence of these stress conditions, the same phagocytosis performed through Mfge8 induces tolerogenic immune responses. As any bacteria, BCG bears pathogen ligands, and its instillation probably creates the stress conditions proposed to favor effector immune responses. As intraperitoneal injection in mice of lipopolysaccharides (a component of gram-negative bacteria's wall) has been recently shown to decrease Mfge8 expression in spleen (Komura et al., 2009) , it would be interesting to check if BCG decreases the level of MFGE8/lactadherin expression in bladders, and/or if inhibiting MFGE8 at the same time as BCG instillation enhances its anti-tumoral activity.
Our work thus provides the first evidence for an immune system-dependent tumor-promoting role of MFGE8/lactadherin in bladder in vivo, both in a carcinogenesis-induced mouse model and in human tumors. Hence, inhibition of MFGE8 expression, by injection of interfering RNA, or function, by a dominant-negative mutant form of MFGE8 or by neutralizing antibodies, could be a promising therapy to prevent bladder tumor progression or relapse.
In addition, the publicly available data showing upregulation of MFGE8 gene expression in several other types of tumors (Figure 1a) , including melanoma for which the protumoral role of MFGE8 has already been documented (Jinushi et al., 2008) , suggest a potential future use of MFGE8-based therapies in other cancers.
Materials and methods
Human bladder samples and affymetrix microarray data Two independent sets of human bladder carcinomas, obtained during transurethral resection or radical cystectomy (Stransky et al., 2006) , and normal urothelial samples obtained from organ donors (Diez de Medina et al., 1997), were used here. All patients provided informed consent. Ethics committees of each Hospital approved the study. Expression of desmin, a specific smooth muscle cell marker, was measured by real-timequantitative-PCR, and tumor samples with expression higher than 25% of the median of five normal bladder smooth muscle were considered overcontaminated with stroma, and thus not included in the analysis. The Human Genome U95A/U95Av2 and U133 Plus 2.0 DNA microarrays (Affymetrix) were used to analyze, respectively, the first and second sets of tumor samples, using previously described procedures (Stransky et al., 2006) .
Immunohistochemistry
Paraffin sections of human bladder carcinomas were stained with anti-human MFGE8/lactadherin (Silvestre et al., 2005) and anti-FOXP3 (Abcam, Cambridge, UK). Numeration of FOXP3-positive cells was performed in five fields of the tumor and peritumoral stroma at Â 400 magnification, and expressed as average cell number per field. 16 carcinomas overexpressing MFGE8 (9 pT2-pT4 þ 7 pTa, pT1) or not (8 pT2-pT4 þ 8 pTa, pT1) were analyzed.
Mice and carcinogenesis
Mice deficient for Mfge8/lactadherin due to a gene-trap insertion of b-galactosidase in the Mfge8 gene (C57Bl/6 background, N8) (Silvestre et al., 2005) were crossed with C57Bl/6 Rag2 À/À mice, to obtain Rag2
Experiments were performed with approval of the Ile-de-France ethical committee for animal experimentation. Bladder carcinogenesis was induced by feeding adult male mice for 14 weeks with 0.05% BBN (TCI Europe) in drinking water (McCormick et al., 1981) . Results from six (respectively two) independent experiments with Mfge8 (respectively Rag2 À/À -Mfge8) mice were pooled. Pathologic evaluation was performed in a 'blind' manner on hematoxylin/ eosin stained paraffin sections of bladders, by pathologists with expertize in urological pathology. Carcinomas were classified according to the 2004 WHO classification of carcinomas of the urinary bladder (pTNM) (Eble et al., 2004) : carcinoma cells confined to the epithelial layer were qualified as in situ carcinoma ¼ pTis or pTa, infiltrating the lamina propria as pT1 and infiltrating the muscularis propria as XpT2. Expression of gene-trapped Mfge8 was evaluated on frozen bladder sections by b-galactosidase reaction as previously described (Silvestre et al., 2005; Veron et al., 2005) .
Blood vessel analysis in mouse bladders
Paraffin sections were stained with anti-vWF antibody (F8/86, Dako, Trappes, France). vWF staining on whole bladder sections was quantified as pixels of gray-level value above value of hematoxylin-stained areas, divided by total pixels of the section (ImageJ software, NIH). A pathologist performed manual counting of blood vessels per field ( Â 400 magnification) of pT1 area of bladder sections. Ultrasound-Doppler imaging of bladder was performed on anesthetized mice before killing, using a 707B probe (Vevo770, VisualSonics, Toronto, Canada). Blood flow was expressed as number of Doppler-positive pixels in bladder epithelium divided by total pixels of epithelium (ImageJ).
Expression of proteins in mouse bladder tumors 25 mg of proteins from lysed half bladders (two of each genotype and pTNM classification, as determined on the corresponding half bladder), were hybridized to glass slide antibody microarrays according to manufacturer's instructions (RayBiotech, Inc., Norcross, GA, USA), and fluorescence signal of each spot was quantified by Mapix software (Innopsys, Inc., Carbonne, France).
Expression of Mfge8 messenger RNA in mouse bladder tumors RNA were extracted from urothelium samples obtained from six control mice, and from bladder tumors of 12 C57Bl/6 male mice treated with BBN for 16 weeks, and killed when presenting signs of weakness, or when tumor encompassed 80% of the bladder, as assessed by ultrasound imaging. RT was performed on 1 mg of RNA using AMV-RT (Finnzyme, Esposo, Finland). Quantitative-PCR was performed in a LightCycler 480 (Roche Diagnostics, Meylan, France) on 100 ng of complementary DNA, using Mfge8-specific Taqman probe (Applied Biosystems, Courtaboeuf, France), or EF1a (Eif1a)-specific primers and SYBRgreen (Thermo Scientific, Villebon sur Yvette, France) as normalization control. Relative Mfge8 expression was calculated as 2
Cp (Eif1a Human studies. Messenger RNA expression levels and Treg numbers in different groups of tumors: Wilcoxon rank sum test. Bladder tumor samples were split between those upregulating MFGE8 (z-score X3) and those with normal or downregulated expression of MFGE8. Identification of genes differentially expressed between these two populations was performed using SAM software, and genes with fold-change 42.5 (or below 0.4) and with SAM q-value less than 5% are listed in Supplementary Table S2 . Genes co-expressed with MFGE8 were identified by pairwise correlation analysis (Spearman's rank coefficient) between expression profiles measured by Affymetrix microarrays of MFGE8 and of each of the other genes of the array. Genes showing correlation value 40.5 or oÀ0.5 in the entire set of tumors are listed in Supplementary Table S2 .
Abbreviations BBN, N-butyl-N-(4-hydroxybutyl) nitrosamine; BCG, Bacillus Calmette-Gue´rin; ECM, extracellular matrix; MFGE8, milk fat globule-epidermal growth factor-factor VIII; pTNM, pathologic tumor node metastasis classification; SAM, significance analysis of microarrays; Tregs, regulatory T cells; MIT, muscle-invasive tumors; NMIT, non-muscle-invasive tumors; VEGF, vascular endothelial growth factor; vWF, von Willebrand Factor.
